Skip to main content

FDA Updates

Lung Cancer, FDA Updates

Tecentriq Approved as First-Line Therapy for Metastatic NSCLC with High PD-L1 Expression

Lung Cancer, FDA Updates

Opdivo-Yervoy First Immunotherapy Combo Approved for First-Line Therapy of Patients with Metastatic NSCLC

FDA Updates

Tabrecta First FDA-Approved Targeted Therapy for Metastatic NSCLC and MET Exon 14 Skipping

FDA Updates

Retevmo First Therapy Approved for 3 Types of Cancers with RET Mutations

FDA Updates

FDA Approves Darzalex Faspro as Subcutaneous Formulation for All Patients with Multiple Myeloma

FDA Updates

Zejula First PARP Inhibitor Approved as First-Line Maintenance Treatment for All Patients with Ovarian Cancer

FDA Updates

FDA Approves New 400 mg Every-6-Weeks Dosing Regimen of Keytruda for All Indications

FDA Updates

Jelmyto First FDA-Approved Therapy for Low-Grade Upper-Tract Urothelial Cancer

Lung Cancer, Thyroid Cancer, FDA Updates

FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib

Sarcoma, FDA Updates

Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma

1
2
3
4
5
6

Page 3 of 13
Results 21 - 30 of 123